India’s pharmaceutical industry is advancing from bulk drug production to complex formulations, strengthening its role in the global healthcare ecosystem
Author: PharmaSignal News Desk
Concerns are mounting in India over the UK-India Free Trade Agreement’s potential impact on access to affordable medicines. Experts fear the deal may weaken compulsory licensing norms, a crucial safeguard allowing generic drug production during public health emergencies
Alembic Pharmaceuticals receives USFDA approval for Tretinoin Cream USP (0.025%). • The cream is therapeutically equivalent to Bausch Health’s Retin-A Cream. •
Aurobindo Pharma invested USD 145 million in its China facility. • The plant commenced operations in November 2024. • Break-even at EBITDA level is expected by
Mounjaro priced from Rs 14,000 for weekly administration. • Offers six dose strengths for personalized treatment. • Targets type 2 diabetes and obesity manageme
Lupin partners with Sandoz for biosimilar ranibizumab commercialization. • Sandoz handles commercialization in multiple regions, excluding Germany. • Lupin will
Roche’s Atezolizumab injection (Tecentriq) approved for subcutaneous use in India. • Approval requires Roche to conduct a Phase IV clinical trial. • Subcutaneou
FDA launches a program to streamline the construction of drug manufacturing sites in the U.S., enhancing domestic production capabilities.